chrisvoncsefalvay/vaers-outcomes huggingface dataset:
6cmx7cm erythema, swelling, slight tender, warm right anterior thigh. Given on 5/10/05 IPV. Started on Cephalexin 250mg, 1 tsp. 1.5 tsp. TID for 10 days.
VACCINE ADMINISTERED BEYOND THE RECOMMENDED HOLD TIME; INCORRECT PRODUCT STORAGE; This spontaneous report received from a health care professional concerned multiple patients. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine (suspension for injection, route of admin not reported, batch number: 201A21A, and expiry: 21-DEC-2021) dose was not reported, administered on 20-SEP-2021 for prophylactic vaccination. No concomitant medications were reported. On SEP-2021, the patient experienced incorrect product storage. On 20-SEP-2021, the patient experienced vaccine administered beyond the recommended hold time. The action taken with covid-19 vaccine was not applicable. The outcome of the vaccine administered beyond the recommended hold time and incorrect product storage was not reported. This report was non-serious.
Approximately 1 month after the 2nd vaccine dose I started to develop chest pain.  After about 6 month I started to develop  heart dysrhythmias.  After 2 years chest pain and heart dysrhythmias are almost a constant and currently being treated with medication.
8/12/04 office visit. Left leg redden, very swollen, warm to touch. Treatment with Zyrtec, Benadryl, Luxiq.
SORE ARM; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 17-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 17-MAR-2021, the subject experienced sore arm. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from sore arm on 18-MAR-2021. This report was non-serious. This case, from the same reporter is linked to 20210335420.
This may not be considered a serious side effect but I thought I should report it. Within hours after receiving the vaccination my arm was very painful. I could not reach or lift it. It actually made any aches in the rest of my body seem worse. I took some TYLENOL which seemed to take the edge off. The next day I still had difficulty reaching and I had large red spots on my arm. I also experienced diarrhea, which I never have. The third day I could start moving my arm more normally but still had tenderness.
Patient received two doses within about 5 minutes of each other.  Patient asked about dose after receiving (2nd).  Patient taken to observation, vital signs HR from 60 to 55.   154/77.  Patient complain of headache and "hard to breath" without signs of swelling, pulse ox normal.   Received acetaminophen 500mg
My menstrual cycle changed dramatically. My periods started happening about 14 days apart for 5 cycles, then I skipped a month of periods, I started my last period on November 14 and suddenly stopped having periods after that one.
Wed. evening and through the night he has a temp up to 102, his body was shaking, weak, sleepy, sore all over
Information has been received from a pharmacist referring to a 63 year old female patient. The patient had no drug reactions/allergies or pertinent medical history. On 25-AUG-2015, the patient was vaccinated with ZOSTAVAX 19400 PFU (lot # L011529 with expiration date 04-JUL-2016) (dose and route were not reported). There was no concomitant medication given. On 27-AUG-2015, the patient experienced itchiness, raised area, warmth and redness at the injection site. The patient spoke to the pharmacist to seek medical attention. Ibuprofen was given for the treatment of the events. No lab diagnostics studies were performed. The outcome of the events was reported as not recovered. Additional information has been requested.
This case was reported by a pharmacist via sales rep and described the occurrence of numbness of upper extremities in a female patient who received SHINGRIX. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced numbness of upper extremities and mobility decreased. On an unknown date, the outcome of the numbness of upper extremities and mobility decreased were recovered/resolved. It was unknown if the reporter considered the numbness of upper extremities and mobility decreased to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. For 2 days the patient experienced arm numbness with limited arm movement, which has since resolved. The patient did not reported whether this affecting her quality of life.
balance problems where I have to hold on to walls, door knobs, or any fixed item; nausea; I my THIRD Booster Covid Vaccine; I my THIRD Booster Covid Vaccine; the shoulder was sore; This is a spontaneous report from a contactable consumer (patient) via Pfizer. A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration, administered in left arm on 08Sep2021 (Lot number was not reported) as dose 3 (booster), single for covid-19 immunisation. Medical history included crohn's disease for 52 years. The patient's concomitant medications were not reported. Immediately after third booster covid vaccine on 08Sep2021, patient's left arm at the shoulder was sore and no problem. But, after 5 days on 13Sep2021 and continuing to date of 19Sep2021, when patient got up in the morning (slowly), patient had balance problems where patient had to hold on to walls, doorknobs, or any fixed item to hold on to, to get to the bathroom. At the same time, patient had bad nausea which continues for hours, or until a 20mg Nausea Pill was taken as a treatment. The outcome of all events was unknown.  The lot number for BNT162B2 was not provided and will be requested during follow up.
Pt c/o chills, aching, dizziness.  No treatment, eventually symptoms resolved.
I experienced bad chills and body aches like having the flu and when I previously had Covid 19; headaches have been really bad.  Chills and body aches are better as of today, 03/03/2021 but the headaches remains.
Patient states that 5 days after receiving the vaccine she experienced extreme muscle and joint pain. She contacted the pharmacy on 10/31 and reported the reaction. I suggested taking 2 Ibuprofens every 4 to 6 hours for a few days to see if that eased the pain and to see her doctor if there was no improvement.
Pharmacy, 1100est, today, left Deltoid im, of pneumovax 23 inj 25mcg/0.5ml PF SYR. Dosage, 0.5. Approx. 1700est noticed a large lump of the left deltoid with pain on movement of shoulder (8), tympanic temp, 100.0F. Slightly warm area. No discoloration or rash. Approx. 5x5inch diameter. Pharmacy notified, triage nurse notified my PCP office. Instructed to take Tylenol and or ibuprofen and apply ice. Continue vitals. If Sx worsen, go to emergency department or wait until Saturday morning and call PCP office for appointment tomorrow.
patient "fainted" after receiving the first dose in the GARDASIL 9 series; Information has been received from a nurse via an employee referring to a 12 years old female patient. The patient was not pregnant. The patient's concomitant medications, pertinent medical history and drug reactions/allergies were unknown by the reporter.  On an unspecified date, the patient was vaccinated with the first dose HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) (frequency, anatomical location, route of administration, lot number and expiration date were unknown) for prophylaxis (reported as cervical cancer prevention) and the patient fainted after receiving vaccination.   No product quality complaint (PQC) was involved. Information about treatment given for adverse event, lab diagnostics/studies performed and medical attention was unknown by the reporter. The outcome of the event was reported as recovered. The causality between the event and HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) therapy was not provided.  Upon internal review, the event of faint was determined to be medically significant.
Left arm ached.  Chills,  body achiness.  Didn't sleep well at night.
Patient had fevers, chills, and hematuria after his booster with Moderna mRNA covid vaccine.  He also had hematuria with his second dose of Pfizer mRNA shot.  Cleared up after a couple of weeks.
Symptom Onset was 08-26-2021. Symptoms included cough, shortness of breath, sore throat, abdominal discomfort, poor appetite, nausea, diarrhea, chest pain, wheezing, headache, fatigue, myalgia, chills and dizziness. The case tested positive for Covid-19 on 08-30-2021. She was hospitalized from 8-30-2021 to 09-03-2021.
On 8/12/03 pt returned to health dept stating arm sore since injection, denied redness or fever. States on 8/11, "it came to a head, scab came off in shower and there was a lot of drainage." Only small amount on bandaid today; no redness noted. Referred to private MD for evaluation.
Moderna  Covid Bivalent  lot # AS7148B expiration 05/17/2023  was admintered on 05/22/2023. Pt was monitor for 30 minutes tolerated vaccine well no adverse reaction reported . Pt was informed of medication error immedately . Nurse called Moderna Manufacturer to confirm if expiration date was extented waiting on call back .
chorioamnionitis; vaccine exposure during pregnancy; Initial unsolicited report received from literature on 18 June 2015.   This case is linked to case ID's: 2015SA090249, 2015SA090258, 2015SA090259, 2015SA090260, 2015SA090261, 2015SA090262. (Same literature, reporter and event)   This case involves five pregnant female patients (age unspecified) who had chorioamnionitis (amniotic cavity infection), after they received DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE [TDAP] (exposure during pregnancy).  Data regarding this pregnancy were received prospectively.    The last menstrual period and estimated date of delivery was not reported.   Gestation period at exposure was unknown.  Medical history, medical treatment, vaccination, family history and concomitant medication were not reported.  On an unknown date, the patients received a dose of suspect DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE (produced by unknown manufacturer) [lot number, expiry date were not reported] via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patients developed a serious chorioamnionitis (amniotic cavity infection), (unknown latency) following the administration of DIPHTHERIA and TETANUS AND ACELLULAR PERTUSSIS VACCINE. This event was assessed as medically significant.  It was also a case of vaccine exposure during pregnancy. (Latency: on the same day of vaccination)   It was not reported if the patients received any corrective treatment for the event.  At time of reporting, the outcome was unknown for the event.  Additionally, at time of reporting, the outcome of the pregnancy was unknown.   There will be no information available on the batch number for this case.  Follow up information received on 19-Apr-2021 regarding an unsolicited valid serious case received from other healthcare professional via health authorities (under reference number: 583520 and US-SA-2015SA090257).  Event exposure during pregnancy updated as diagnosis from symptom. Report type of the case updated (unsolicited literature to unsolicited non-literature), listedness updated, seriousness for event exposure during pregnancy updated (serious to non-serious) and complete narrative updated accordingly.; Sender's Comments: Follow-up information was received on 19-Apr-2021 changes the previous assessment of the case: This case involved five pregnant female patients (age unspecified) who had exposure during pregnancy and amniotic cavity infection after the administration of TDAP vaccine. Time of onset was unknown for amniotic cavity infection and compatible for exposure during pregnancy. Further information regarding concurrent condition during vaccination, previous vaccination and tolerance, laboratory investigations excluding alternative etiologies for the reported event are needed to fully assess this case. Based upon the reported information, the role of the suspect vaccine cannot be assessed.
diaphoresis; flushed; dizziness; This spontaneous report was received from a Registered nurse concerning  a 71 year old female patient. There was no information about the patient's medical history, concurrent conditions or concomitant medication. On 03-DEC-2020, the patient was vaccinated with a dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23), prefilled syringe, 0 .5 milliliter ,lot # T027110,expiration date: 23-MAR-2022, intramuscular in the right arm for Routine immunization.  On the same date the patient experienced hyperhidrosis, dizziness and flushing, after injection. Patient was given diphenhydramine hydrochloride (BENADRYL) 50 mg tablet, was able to recover and ambulate on her own at discharge. No laboratory/diagnostic tests were reported. The outcome of hyperhidrosis, dizziness and flushing was reported as recovered, on the same date. The patient seek unspecified medical attention. The causal relationship between the aforementioned events and  polyvalent (23-valent)(PNEUMOVAX23)was not reported. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T027110; expirationdate: 23-MAR-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent
left arm with a rash; left arm redness; left arm itchy; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (left arm redness), PRURITUS (left arm itchy) and RASH (left arm with a rash) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination.     Concomitant products included ATENOLOL, HYDROCHLOROTHIAZIDE, CITALOPRAM HYDROBROMIDE (CELEXA [CITALOPRAM HYDROBROMIDE]) and TRAZODONE for an unknown indication.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Feb-2021, the patient experienced PRURITUS (left arm itchy). On 21-Feb-2021, the patient experienced ERYTHEMA (left arm redness). On an unknown date, the patient experienced RASH (left arm with a rash). At the time of the report, ERYTHEMA (left arm redness), PRURITUS (left arm itchy) and RASH (left arm with a rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medications were reported.
RAPID HEARTBEAT; This spontaneous report received from a patient via a social media  via a company representative concerned a female of unspecified age. The patient's height, and weight were not reported. The patient's past medical history included: headache, rapid heartbeat, and heart palpitation, and concurrent conditions included: coffee drinker, and stress. The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin, and batch number were not reported) dose not reported, 1 total, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced rapid heartbeat (dose number in series 1). She stated it is hard to tell if side effects are from vaccines or just the usual stuff we get anyway. She had headaches, rapid heartbeat, heart palpitations with no vaccine in body. She also stated that so many people's had anxiety after getting these covid-19 vaccines. That's part of the problem. No doubt there are those that will have side effects tho. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient received non-company suspect vaccine included: bnt 162 (dose number in series 2) (form of admin, route of admin, and batch number were not reported) dose not reported, start therapy date were not reported for prophylactic vaccination.  On an unspecified date, the patient again experienced rapid heartbeat (dose number in series 2). The action taken with bnt 162 was not applicable. The patient recovered from rapid heartbeat. This report was non-serious.; Sender's Comments: V0 Medical assessment comment not required as per standard operating procedure as the case assessed as non-serious.
Hospitalization for Sepsis due to pneumonia from COVID-19 on dates 12/5/2022- 12/8/2022. Treated with vitamin C 1,000 mg PO daily, vitamin D 25 mcg PO daily, zinc 50 mg PO daily.
Very labored breathing 2 d after given shot, had to be put on O2 at 3 L,  24 hours since 1/14/10.
Shortly after shot, patient's arm "blew up into big hive from shoulder to elbow" and then "felt like death for a week."  It took 4 days for the swelling in the arm to go down.  Patient reports not being able to leave bed or home for multiple days, felt swollen and inflamed all over skin to the point of skin hurting from normal clothing.  Patient reports horrible migraines in that week after the shot, and still experiences migraines today from it.  Patient reports having a new burning pain in hands and feet that started the day after the shot and still persists even today, months later.   Patient reports this pain limiting her daily activities.
10/30/2021, came down with a upper chest respiratory infection headache, a runny nose and asthma. Nov/2021 antibiotics Zpac, 12/13/2021 azithromycin and Dec. 12/28/2021, I went through antibiotics steroids. 01/24/2022- Pulmonologist office and thought that I had pneumonia, was injection prednisone and 7 day course of steroid and this resolved my upper respiratory issue. Went through three rounds of antibiotics levofloxacin and prednisone on this ultimately resolved the respiratory issues.
A report was received from a health care professional on 13 November 2003 concerning an 87 year old female vaccinee who inadvertently received 2 doses of Fluvirin on unspecified dated, over a period of a couple of days. On unspecified dates, the vaccinee inadvertently received 2 doses of Fluvirin over a period of a couple of days. No adverse symptoms were reported at the time of reporting. There was insufficient information to determine the reporter's causality assessment. Follow up pending.
Information has been received from a nurse concerning an immunocompromised female with a history of spleen removal who was vaccinated with a 0.65 mL dose of Zostavax (Oka/Merck).  The nurse reported that the patient had a "bad reaction".  It was unknown if medical attention was sought.  At the time of this report, the outcome was unknown.  No further information is available.
reports calcification bumps on her arms distal to elbows prior to start got bigger; md told her that her inflammation levels went down; This is a spontaneous report from a from a contactable other hcp via Pfizer-sponsored program.  A 66-years-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection; Lot Number and Expiration date was not reported), via an unspecified route of administration on 17Apr2021(at the age of 66-year-old) as dose 2, single for covid-19 immunization. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection; Lot Number and Expiration date was not reported), via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunization. Patient reported her md advised her to hold xeljanz for one week before and one week after each of her two covid-19 vaccinations. Reported her second vaccination was on 17Apr2021, and she re-started xeljanz on 20Apr2021 and she also reported the calcification bumps on her arms distal to elbows prior to start got bigger during holds, unknown after re-start. She reported, md told her that her inflammation levels went down after start of therapy 27Dec2020, did not specify blood labs or values. md aware. The clinical outcome of events were unknown.  No follow attempts are needed; information about lot/batch number cannot be obtained.
pt admitted to SNF with acute diastolic congestive heart failure and history of COVID pneumonia; (COVID test on 9/12/2021); was treated with antibiotics; in SNF for PT/OT, O2 supplementation; aggressive comfort measures; pt passed away in the SNF
Itching, tenderness then pain upper left arm, skin redness and slightly bumpy.  By the evening, symptoms got worse.  I took ibuprofen, benadryl ointment was applied after using ice at site.
I started having a sore throat, a little tired. I took Paxlovid after I called my doctor, April 4th I tested Negative, later on the day, 10 days on the COVID-19, On April 5th I tested positive. The symptoms came back really strong.  I got Paxlovid on March 26.
on 19JUN 8 days post vax pt devel 10 papular & vesicular rash on chest back & face;
Immediately after the vaccination patient complained about extreme anxiety. We gave a dose of Benadryl. Patient said it might not be allergy but panic attack. EMT was called and the patient felt fine after the EMT attended.
Information has been received from a physician referring to a male patient of unknown age. In April 2014 the patient was vaccinated with the first dose of GARDASIL (strength, dose, route and lot# were not reported). The patient received his second dose of GARDASIL (dose, route and lot# were not reported) late on 27-FEB-2015. No adverse events were reported. Additional information has been requested.
Pt recvd vax JUN92 & 24-36 hrs following vax pt devel hypersensitivity reaction described as urticaria & lymphangioedema;
Initial report received from a healthcare professional (Nurse) on 23 October 2012. A female patient, whose age, medical history and concomitant medication were not reported received an intradermal dose of FLUZONE vaccine; lot number UT4471AA (anatomical site of administration was not reported), on an unspecified date. On an unspecified date the patient's arm had swollen and she considered it as "severe" type of reaction. The corrective treatment and lab investigations were not reported. At the time of this report, outcome was not reported. Documents held by sender: none.
During administration the attachable needle came loose resulting in vaccine spillage and an incomplete injection. It is very likely that less than 50% of medication was injected but patient did not want to repeat the vaccination in the opposite arm which is the recommendation by the cdc
PEDIATRIC PATIENT WAS ADMINISTERED AN ADULT DOSE OF HEPATITIS-A VACCINE. PATIENT WAS PLACE IN OBSERVATION FOR AT MINIMUM OF 45 MINUTES FOR ANY SIDE EFFECTS. NO SIDE EFFECTS WITNESSED OR REPORTED.